Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai MicroH Therapeutics, has received approval from the US FDA to commence a Phase I clinical trial for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia. This approval marks a significant step as no live biotherapeutic product has been approved globally for this condition, highlighting the company’s potential impact on the market and its commitment to innovative healthcare solutions.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating in the pharmaceutical industry. The company focuses on the development and production of pharmaceutical products, with a market emphasis on innovative drug development and healthcare services.
Average Trading Volume: 5,778,567
Technical Sentiment Signal: Sell
Current Market Cap: HK$61.89B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue